drugset / Trial / NCT02140372

Anti-platelet Effects of Colchicine in Healthy Volunteers

NCT02140372

Phase 4 Completed 10 enrolled NYU Langone Health
NaSingle-groupOpen-labelTreatment

Summary

This is a pilot study. Volunteers will be given 1.8 mg (1.2 mg followed by 0.6 mg one hour later), 1.2 mg, or 0.6 mg of colchicine. Blood will be collected prior to drug administration, 2 hours after colchicine administration, and 24 hours after colchicine administration via the antecubital vein and evaluated for markers of platelet activity and inflammation.

Timeline

Start
2014-05
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Colchicine Small molecule 0.6 mg
Subject Colchicine Small molecule 1.2 mg
Subject Colchicine Small molecule 1.8 mg

Indications

No indication recorded.